Rhone Ma Holdings BhdXKLS:5278 61 Net Margin % is 6.41% as of Mar. 2026, which is 2% below its 10-year median of 6.54. GuruFocus rates XKLS:5278 with a GF Score™ of 61/100 and a GF Value™ of RM0.80 (Modestly Undervalued). Among 957 Drug Manufacturers companies, Rhone Ma Holdings Bhd ranks better than 52.25% on this metric.
The historical rank and industry rank for Rhone Ma Holdings Bhd's Net Margin % or its related term are showing as below:
XKLS:5278'
s Net Margin % Range Over the Past 10 Years
Min: 4.97 Med: 6.54 Max: 10.11
Current: 6.28
XKLS:5278's Net Margin % is ranked better than 52.25% of 957
companies
in the Drug Manufacturers industry
Industry Median: 5.58
vs XKLS:5278: 6.28
Rhone Ma Holdings Bhd (XKLS:5278) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Rhone Ma Holdings Bhd Net Margin % Related Terms
Rhone Ma Holdings Bhd Net Margin % Historical Data
* Premium members only.
The historical data trend for Rhone Ma Holdings Bhd's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:5278 vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rhone Ma Holdings Bhd's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhone Ma Holdings Bhd Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rhone Ma Holdings Bhd's Net Margin % distribution charts can be found below:
* The bar in red indicates where Rhone Ma Holdings Bhd's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhone Ma Holdings Bhd (XKLS:5278) has a Net Margin % of 6.41% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Rhone Ma Holdings Bhd and its competitors. This is near median its historical median of 6.54. Over the past decade, Rhone Ma Holdings Bhd's Net Margin % has ranged from 4.97 to 10.11. According to the industry distribution chart, Rhone Ma Holdings Bhd ranks #457 out of 957 companies in the Drug Manufacturers industry, placing it in the top 47.8%.
Is Rhone Ma Holdings Bhd's Net Margin % too high?
Rhone Ma Holdings Bhd's current Net Margin % of 6.41% is near median its 10-year median of 6.54. Over the past 10 years, this metric has ranged from a low of 4.97 to a high of 10.11. The Drug Manufacturers industry median Net Margin % is 5.58. Rhone Ma Holdings Bhd's value of 6.41% is 14.9% above this industry median. Based on the distribution chart, Rhone Ma Holdings Bhd ranks #457 out of 957 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Rhone Ma Holdings Bhd has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rhone Ma Holdings Bhd's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rhone Ma Holdings Bhd ranks #457 out of 957 companies for Net Margin %. This puts Rhone Ma Holdings Bhd in the upper half of its industry. The industry median Net Margin % is 5.58. Rhone Ma Holdings Bhd's value of 6.41% is 14.9% above this benchmark. Historically, Rhone Ma Holdings Bhd's own Net Margin % has ranged from 4.97 to 10.11 over the past decade. While the company's 10-year median is 6.54 vs. the industry median of 5.58, Rhone Ma Holdings Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.58, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhone Ma Holdings Bhd's current Net Margin % of 6.41% is 14.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Rhone Ma Holdings Bhd and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhone Ma Holdings Bhd's current Net Margin % is 6.41%, which is near median its own 10-year median of 6.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhone Ma Holdings Bhd stock overvalued right now?
Based on GuruFocus' analysis, Rhone Ma Holdings Bhd (XKLS:5278) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.80, compared to a current price of RM0.69 — trading 13.8% below its estimated fair value. The current Net Margin % is 6.41%, which is near median its 10-year median of 6.54 and 14.9% above the Drug Manufacturers industry median of 5.58. Rhone Ma Holdings Bhd's overall GF Score™ is 61/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Rhone Ma Holdings Bhd (XKLS:5278), the current Net Margin % is 6.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rhone Ma Holdings Bhd (XKLS:5278) Overvalued in 2026?
Based on GuruFocus' analysis, Rhone Ma Holdings Bhd stock appears to be undervalued.
The current stock price of RM0.69 is trading 13.8% below its estimated GF Value™ of RM0.80.
GuruFocus considers Rhone Ma Holdings Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:5278:
Net Margin %: 6.41% (near median its 10-year median of 6.54)
GF Value™: RM0.80 vs. price of RM0.69 (13.8% below fair value)
Industry Position: 14.9% above the Drug Manufacturers median (#457 of 957)
No single metric tells the full story. See the XKLS:5278 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rhone Ma Holdings Bhd, along with its subsidiaries, is mainly involved in the provision of end-to-end animal health solutions. The Group provides veterinary consultation services, diagnostic laboratory analyses, R&D, and is engaged in the manufacturing and distribution of animal health products. Its reportable segments are: Animal health products and equipment, Food ingredients, and Others. The majority of its revenue is generated from the Animal health products and equipment segment, which is engaged in marketing, trading, distribution, and manufacturing of animal health products and equipment, such as pharmaceuticals, vaccines, feed additives, pesticides, and others. Geographically, the Group's operations are predominantly located in Malaysia.
61GF Score
Get the complete analysis for XKLS:5278
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:5278 has been successfully added to your 
